Burden of snakebite and socio-economic consequences with a focus on Africa
1
Infectious & Tropical Diseases Unit, Bayero University Kano, Kano, Nigeria
Popul. Med. 2026;8(Supplement Supplement 1):A410
ABSTRACT
ABSTRACT:
Snakebite envenoming (SBE) is a major cause of death, illness, and long-term disability in rural sub-Saharan Africa (SSA), with a burden second only to that in Asia. The true magnitude of SBE in SSA is likely underestimated due to substantial sub-regional variation and the presence of endemic hotspots, particularly across the savannah regions of West, Central, and East Africa. A recent meta-analysis estimated 268,471 SBE cases annually (95% CI: 221,868-314,782) across 41 SSA countries, with a mortality rate of 4.6%, amputations in 5.5% of cases, and post-traumatic stress disorder affecting 20.6% of survivors.1 Among children, an estimated 178,491 cases and 4,346 deaths occur each year.2 Overall, the SBE burden translates to approximately 1.03 million disability-adjusted life years (DALYs) annually in SSA (95% CI: 0.80-1.28 million).1 Household surveys in Mozambique suggest that routine surveillance may underestimate incidence and mortality by up to 10-fold and 30-fold, respectively.3 This burden is comparable to, or exceeds, that of many neglected tropical diseases, highlighting the need for commensurate resource allocation for SBE control.4 Incidence of SBE shows strong seasonal variation, with climate change exacerbating risk by expanding snake habitats and increasing human–snake contact. The disease disproportionately affects poor, rural, and agricultural communities, particularly young subsistence farmers, and also undermines livestock production and household livelihoods. Mortality is closely linked to socioeconomic deprivation, with the highest fatality rates observed among children.5 Although antivenom remains the cornerstone of effective and highly cost-effective treatment, access is severely limited by high cost and poor availability. Achieving the World Health Organization’s Roadmap targets to halve snakebite incidence, mortality, and long-term disability will require sustained,6 coordinated efforts to expand timely access to quality care and ensure reliable antivenom supply across affected regions.
Snakebite envenoming (SBE) is a major cause of death, illness, and long-term disability in rural sub-Saharan Africa (SSA), with a burden second only to that in Asia. The true magnitude of SBE in SSA is likely underestimated due to substantial sub-regional variation and the presence of endemic hotspots, particularly across the savannah regions of West, Central, and East Africa. A recent meta-analysis estimated 268,471 SBE cases annually (95% CI: 221,868-314,782) across 41 SSA countries, with a mortality rate of 4.6%, amputations in 5.5% of cases, and post-traumatic stress disorder affecting 20.6% of survivors.1 Among children, an estimated 178,491 cases and 4,346 deaths occur each year.2 Overall, the SBE burden translates to approximately 1.03 million disability-adjusted life years (DALYs) annually in SSA (95% CI: 0.80-1.28 million).1 Household surveys in Mozambique suggest that routine surveillance may underestimate incidence and mortality by up to 10-fold and 30-fold, respectively.3 This burden is comparable to, or exceeds, that of many neglected tropical diseases, highlighting the need for commensurate resource allocation for SBE control.4 Incidence of SBE shows strong seasonal variation, with climate change exacerbating risk by expanding snake habitats and increasing human–snake contact. The disease disproportionately affects poor, rural, and agricultural communities, particularly young subsistence farmers, and also undermines livestock production and household livelihoods. Mortality is closely linked to socioeconomic deprivation, with the highest fatality rates observed among children.5 Although antivenom remains the cornerstone of effective and highly cost-effective treatment, access is severely limited by high cost and poor availability. Achieving the World Health Organization’s Roadmap targets to halve snakebite incidence, mortality, and long-term disability will require sustained,6 coordinated efforts to expand timely access to quality care and ensure reliable antivenom supply across affected regions.
| eISSN: | 2654-1459 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
